#必胜客跨界卖烤串6元一串羊肉串#【羊肉串6元，有歌手驻唱，卖披萨的必胜客开始做"夜宵生意"】蓝 鲸新闻记者发现，近日必胜客上海大宁门店"改头换面"，除传统的"必胜客"招牌外，还增加了"必胜炙 烤串"的字样。 9rdl. 名胜灭烤串. ant, "必胜炙烤串"的首家门店并非独立门店，而是在必胜客门店的基础上辟出一块专门的区域售卖烤串，运 营时间也有明显区隔，仅在下午5点到凌晨12点运营。走进门店后，服务员会特意询问，是来吃披萨还 是吃烤串。 必胜客跨界的操作，让人联想到了此前海底捞布局多元餐饮赛道的"红石榴计划"，事实上不止海底捞， 2025年不少餐饮品牌都在通过开设子品牌或新增其他品类业务的方式寻找"第二增长曲线"。 不过蓝鲸新闻记者就餐的傍晚时段店内上座率不高，就餐人群中部分为博主探店打卡，配合店内的新店 营销活动。此外蓝鲸新闻记者发现，为配合烧烤夜宵气氛，店内也设置驻唱歌手。@蓝鲸新闻 和传统必胜客菜单不同，目前必胜炙烤串独立菜单，主要品类分为各类烤串、酒精饮料特调等。价格来 看，烤串单价在3-19元不等，其中羊肉串6元/串，烤羊排19元/串，大众点评数据显示，人均消费约为70 元，与主流连锁烧烤品牌相 ...

Core Viewpoint - Fasenra (benralizumab) has received approval from the NMPA for the treatment of adult eosinophilic granulomatosis with polyangiitis (EGPA), marking a significant advancement in the treatment options available for this rare autoimmune disease [1][4]. Group 1: Clinical Research and Approval - The approval is based on the results of the MANDARA global Phase III clinical trial, which is the first head-to-head study comparing the efficacy and safety of benralizumab with mepolizumab in patients with refractory EGPA [1][5]. - In the benralizumab treatment group, nearly 60% of patients achieved remission, consistent with the mepolizumab group, while 41% of patients could completely discontinue oral corticosteroids (OCS), compared to 26% in the mepolizumab group [1][5]. - The open-label extension study of the MANDARA trial showed that patients switching from mepolizumab to benralizumab had an OCS discontinuation rate of up to 43.5% [1]. Group 2: Disease Background and Treatment Challenges - EGPA is a rare autoimmune disease characterized by eosinophil infiltration and necrotizing granulomatous inflammation, primarily affecting the respiratory system and leading to severe complications if untreated [2][4]. - Current treatment options are limited, with many patients requiring high-dose OCS and experiencing frequent relapses, as approximately 75% of patients have not achieved remission despite multiple therapies [2][4]. Group 3: Expert Opinions and Future Directions - Experts highlight that benralizumab's approval represents a milestone in providing targeted therapy for EGPA, potentially improving patient outcomes and reducing reliance on corticosteroids [3][4]. - The subcutaneous administration of benralizumab every four weeks enhances treatment convenience for patients, addressing a significant need for effective and safe treatment options [3][4]. - AstraZeneca plans to continue exploring the potential of benralizumab in other eosinophil-related diseases, aiming to innovate treatment strategies in this area [3][6].

（企业公众号） (编辑：林辰)关键字： 今世缘 白酒 近日，今世缘酒业官方公众号发布2026今世缘发展大会召开的消息。当中披露，"十四五"期间，今世缘 交出"量质双升，基础更牢"答卷。主要指标实现翻番，2023年营收突破百亿大关，实现历史性跨越。市 场拓展纵深推进，省内市场占有率大幅增长，省外超千万地级板块达40个。品牌产品矩阵优化，强化国 缘V系高端形象，推动四开、对开、淡雅大单品战略，今世缘品牌破局重塑，推动高沟品牌经典活化。 营销变革有序有力，推进组织变革，优化组织架构，锻造组织能力，践行"厂商一家人"理念，强力推 进"大营销管控"体系培训，促进主体优化提升。资源要素拔节起势，制曲产能和原酒产能分别突破8万 吨，陶坛贮能达30万吨，实施战略性人才"3333工程"，构建核心人才梯队。 今世缘酒业党委书记、董事长、总经理顾祥悦指出，2025年是"十四五"收官之年，今世缘厂商团队承压 奋进，拼出实干争先新图景。企业坚守战略，稳住市场基本盘，国缘V3强势出圈，省内外、电商多渠 道协同发展，管理体系持续完善，大客户开发成效显著；立足改革创新，激活动力源，供应、生产、销 售、消费端多维度提质升级；提升厂商协同，聚力 ...

此次获批1＃住宅楼104套房源，拟售均价约7.48万元/㎡。这是该项目二期首次取证，在一期的基础 上，增添了架空层、邻里共享空间、开敞阳台和设备平台等"好房子"元素。项目整体规划11栋6-23F洋 房及高层，共623套住宅，容积率2.8，产品为缦云系，主打纯高端大平层改善产品，主力建面199-350 ㎡，一梯一户，层高3.3米，准现房。 产品为缦云系 12月29日，位于北京城市副中心0401街区的缦云ONE取得预售许可证，备案名缦云福苑二期。 ...

Core Viewpoint - Lin Qingxuan officially listed on the Hong Kong Stock Exchange on December 30, with a share price of HKD 88, representing a rise of over 13.15%, and a total market capitalization of approximately HKD 12.29 billion [1] Group 1: Company Performance - Lin Qingxuan focuses on the anti-wrinkle and firming skincare industry, providing high-end skincare solutions with natural camellia ingredients [1] - Revenue is projected to grow from CNY 691 million in 2022 to CNY 1.21 billion in 2024, reflecting a compound annual growth rate (CAGR) of 32.3% [1] - In the first half of 2025, revenue is expected to increase by 98.3% to CNY 1.05 billion compared to CNY 530 million in the same period of 2024; adjusted net profit is anticipated to rise from CNY 92 million to CNY 200 million, a year-on-year increase of 117.4% [1] Group 2: Future Strategy - The founder, Sun Laichun, stated the company will continue to invest in research and development in dermatology, botany, and cutting-edge skincare technology [1] - There will be an emphasis on brand building and retail store expansion, alongside upgrading popular products such as camellia oil, golden pearl essence, and black gold cream to enhance customer skincare experiences and create higher value for shareholders [1]

Core Insights - The announcement of Innovent Biologics being included in the Hang Seng Index marks a significant milestone, as it becomes the first Chinese innovative pharmaceutical company to transition from Biotech to Biopharma under the Hong Kong Stock Exchange's 18A system [1] - This achievement aligns with the company's recognition as "Annual High-Quality Development Listed Company" in the 2025 New Consumption and New Economy Awards [3] Group 1: Market Position and Financial Performance - Innovent Biologics has transitioned from a story-driven early biotech firm to a stable investment asset, supported by 18 commercialized innovative drugs and a complete industry chain from R&D to production [4] - The company's revenue has surged from 1 billion yuan in 2019 to 9.4 billion yuan in 2024, representing an 840% increase over five years, with expectations to exceed 10 billion yuan in 2025 [4] - The inclusion in the Hang Seng Index is expected to attract billions of dollars in passive capital inflow, optimizing the investor structure and reducing stock price volatility [4] Group 2: Product Development and Innovation - Innovent's mature products, such as Sintilimab, continue to provide stable cash flow, while new products like MaShidu Peptide strengthen its market position in the weight management sector [5] - The company has achieved significant milestones in R&D, with its MaShidu Peptide being the first globally approved dual-target receptor agonist for GCG/GLP-1, addressing specific health issues in Chinese patients [6] - Innovent's innovative capabilities are further demonstrated by its IL-23p19 monoclonal antibody showing strong efficacy in clinical trials for psoriasis, and the introduction of China's first IGF-1R antibody for thyroid eye disease [6] Group 3: Globalization and Strategic Partnerships - Innovent's globalization strategy has evolved from licensing to co-development, exemplified by a landmark $11.4 billion global strategic partnership with Takeda Pharmaceuticals [7] - The partnership adopts a "Co-Co" model, allowing Innovent to participate deeply in global clinical design and commercialization processes, marking a shift from traditional licensing agreements [7] - This collaboration signifies a critical step for Chinese pharmaceutical companies to engage in high-standard international platforms, enhancing their global competitiveness [8] Group 4: Overall Impact and Future Outlook - Innovent Biologics' journey from a local lab to a prominent player in the Hang Seng Index illustrates a successful model for the sustainable development of China's biopharmaceutical industry [9] - The company's integrated approach of capital, product strength, and globalization serves as a promising template for future growth and stability in the sector [9]

【#众泰汽车董事长上任两个月后辞职#】12月29日，众泰汽车公告，公司董事长李立忠因个人家庭原因 申请辞去董事长、董事职务，同时辞去董事会战略委员会主任委员、提名委员会委员职务。李立忠的辞 职不会导致公司董事会成员低于法定最低人数，不会影响公司董事会的正常运行，亦不会对公司的日常 经营产生不利影响，辞职报告自送达董事会之日起生效。此外，公司董事会提名韩必文为第九届董事会 非独立董事候选人，任期自股东会审议通过之日起至第九届董事会届满之日止。 此前10月30日，众泰汽车新董事会正式履职，李立忠任董事长。直到此次离职，李立忠担任众泰汽车董 事长仅两个月时间。 12 月 29 目, 公司董事长李立忠因个人家庭原因申请辞去董 事长、董事职务,同时辞去董事会战略委员会 主任委员、提名委员会委员职务。李立忠的辞 职不会导致公司董事会成员低于法定最低人 数,不会影响公司董事会的正常运行,亦不会 对公司的日常经营产生不利影响，辞职报告自 送达董事会之日起生效。此外,公司董事会提 名韩必文为第九届董事会非独立董事候选人, 任期自股东会审议通过之日起至第九届董事会 届满之日止。 此前10月30日,众泰汽车新董事会正式履 职,李立 ...

近年来，医疗健康行业正加速探索大模型、智能体等AI前沿技术的创新应用。12月29日，北京大学人 民医院（以下简称"北大人民医院"）与蚂蚁健康联合组建的"医学人工智能创新联合研究中心"正式揭牌 成立，旨在共同推动人工智能技术在医疗健康领域的前沿研究和应用落地。 同期，由北大人民医院牵头，联合中国信息通信研究院（以下简称"中国信通院"）、蚂蚁健康及多家顶 尖医院共同编制的全国首个外科领域 "AI医生" 标准正式面世，在医学AI的技术应用标准、规范上迈出 了系统化的关键一步。 北大人民医院院长、中国工程院院士王俊在揭牌仪式上表示，该研究中心将聚焦临床真实痛点，重点探 索AI在专病智能诊疗、临床决策支持及健康管理模型等方向的创新应用，全力推动将科研成果转化为 更普惠、更可及的医疗健康服务。 同时，由王俊院士等6名院士领衔，全国超500位医生已在"蚂蚁阿福"App上线了"名医AI分身"，为公众 提供7X24小时的专业健康咨询服务，让顶级专家的优秀经验更普惠地服务大众健康。 《2025年政府工作报告》明确提出加快开展"人工智能+医疗健康"工作，培育医疗健康行业新质生产 力。同年8月，国务院发布《关于深入实施"人工智能+" ...

2026年1月1日起，东航免费WiFi服务将扩大到所有宽体机执飞的国内航班。此前，东航免费WiFi服务 只覆盖空中快线，范围扩大后，东航所有宽体机执飞的国内航班(不含港澳台)头等舱和公务舱旅客可免 费畅享高速版空中WiFi，经济舱旅客可免费畅享标准版(焕新)空中WiFi。 (东方航空) ...

【#中芯国际拟406亿收购中芯北方#】#中芯南方注册资本增至100.773亿美元#12月29日晚，中芯国际公 告称，公司拟向国家集成电路基金等5名中芯北方股东发行股份购买其所持有的标的公司49%股权，交 易价格406亿元。 此外，中芯国际同时公告，中芯控股与国家集成电路基金、国家集成电路基金二期等订立新合资合同及 新增资扩股协议，中芯南方注册资本将由65亿美元增加至100.773亿美元。中芯控股、国家集成电路基 金、国家集成电路基金二期、国家集成电路基金三期、上海集成电路基金、上海集成电路基金二期、泰 新鼎吉、先导集成电路基金将分别持有中芯南方41.561%、9.392%、14.885%、8.361%、7.939%、 11.253%、5.545%及1.063%股权。（21世纪经济报道） #中芯国际拟购买中芯北方49%股权# 本次交易完成后，中芯国际将持有中芯北方100%的股权，中芯北方将成为公司的全资子公司。中芯北 方主要为客户提供不同工艺平台的12英寸集成电路晶圆代工及配套服务。 本次交易有利于进一步提高上市公司资产质量、增强业务上的协同性，促进上市公司的长远发展。交易 前后上市公司的主营业务范围不会发生变 ...